Biotech Values

[DewDiligence]

OCRX—I think it was BMO that had a note that said the upsizing in the trial would increase the power. I am not a stats guru but if the effect size is smaller unless they increased the n significantly more than necessary I don't see how the power could be higher.

You’re correct and BMO is out to lunch.

After the enrollment-target increase from 140 to 230, I’m assuming the statistical power of the revised trial is approximately the same as the 80% in the company’s original model. However, if my assumption were wrong, the power in the revised trial would be lower than 80%—in no way can it be higher.